Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 33.30M P/E - EPS this Y 43.10% Ern Qtrly Grth -
Income -40.42M Forward P/E -5.56 EPS next Y 100.00% 50D Avg Chg -1.00%
Sales 42.26M PEG - EPS past 5Y - 200D Avg Chg 12.00%
Dividend N/A Price/Book 0.84 EPS next 5Y - 52W High Chg -49.00%
Recommedations 2.00 Quick Ratio 4.00 Shares Outstanding 13.32M 52W Low Chg 72.00%
Insider Own 47.41% ROA -16.65% Shares Float 5.92M Beta 0.39
Inst Own 2.72% ROE -59.42% Shares Shorted/Prior 127.33K/53.13K Price 2.50
Gross Margin 63.84% Profit Margin -95.64% Avg. Volume 30,411 Target Price 12.00
Oper. Margin -59.38% Earnings Date Apr 24 Volume 18,307 Change 2.04%
About CASI Pharmaceuticals, Inc.

CASI Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapeutics and pharmaceutical products in the People's Republic of China, the United States, and internationally. It offers EVOMELA, an intravenous formulation of melphalan for use as a conditioning treatment prior to stem cell transplantation, and as a palliative treatment for patients with multiple myeloma. The company's other hematology/oncology assets in pipeline include CNCT 19, an autologous CD19 CAR-T investigative product; BI-1206, novel anti-Fc?RIIB antibody, for the treatment of solid tumors and relapsed/refractory non-hodgkin lymphoma; CB-5339, a novel VCP/p97 inhibitor that focuses on valosin-containing protein (VCP)/p97 as a novel target in protein homeostasis, DNA damage response, and other cellular stress pathways for therapeutic use in the treatment of patients with various malignancies; and CID-103, a human IgG1 anti-CD38 monoclonal antibody. The company has licensing agreements with Juventas Biotechnology (Tianjin) Co., Ltd.; BioInvent International AB; Black Belt Therapeutics Limited; Cleave Therapeutics, Inc.; and Acrotech Biopharma L.L.C. to develop and commercialize its commercial product EVOMELA. It also has distribution agreements with China Resources Pharmaceutical Commercial Group International Trading Co., Ltd; Pharmathen Global BV; and Riemser Pharma GmbH. CASI Pharmaceuticals, Inc. was incorporated in 1991 and is based in Beijing, the People's Republic of China.

CASI Pharmaceuticals, Inc. News
03/28/24 CASI PHARMACEUTICALS ANNOUNCES FOURTH QUARTER AND FULL-YEAR 2023 BUSINESS AND FINANCIAL RESULTS
03/05/24 CASI Pharmaceuticals Report Positive Interim Phase 1 Data For BI-1206 In The Treatment Of Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma In China
02/16/24 CASI PHARMACEUTICALS ANNOUNCES FIRST DOSING OF FOLOTYN® IN CHINA
12/18/23 CASI Pharmaceuticals, Inc.'s (NASDAQ:CASI) Price Is Right But Growth Is Lacking After Shares Rocket 33%
11/16/23 Analysts Expect Breakeven For CASI Pharmaceuticals, Inc. (NASDAQ:CASI) Before Long
11/14/23 CASI PHARMACEUTICALS ANNOUNCES THIRD QUARTER 2023 BUSINESS AND FINANCIAL UPDATES
11/08/23 CASI PHARMACEUTICALS ANNOUNCES MARKET APPROVAL OF CNCT19 BY CHINA NMPA
08/11/23 CASI PHARMACEUTICALS ANNOUNCES SECOND QUARTER 2023 BUSINESS AND FINANCIAL UPDATES
08/01/23 Mundipharma International Corporation Limited, Mundipharma Medical Company, and Acrotech Biopharma Inc. Enter Agreement to Transfer License of FOLOTYN® (Pralatrexate) in China to CASI Pharmaceuticals
07/20/23 CASI Pharmaceuticals Acquires Global Intellectual Property Rights to Cleave Therapeutics' VCP/P97 Inhibitor CB-5339
05/28/23 We Think CASI Pharmaceuticals (NASDAQ:CASI) Needs To Drive Business Growth Carefully
05/17/23 CASI PHARMACEUTICALS ANNOUNCES FIRST QUARTER 2023 FINANCIAL RESULTS
04/26/23 CASI Pharmaceuticals Files Annual Report on Form 20-F for Fiscal Year 2022
04/26/23 CASI PHARMACEUTICALS ANNOUNCES FOURTH QUARTER AND FULL-YEAR 2022 FINANCIAL RESULTS
04/17/23 Improved Revenues Required Before CASI Pharmaceuticals, Inc. (NASDAQ:CASI) Stock's 114% Jump Looks Justified
CASI Chatroom

User Image Bigeyes2 Posted - 16 hours ago

$CASI Swing

User Image Plasma_star_9 Posted - 18 hours ago

$CASI What? They have sales income? What a pleasant surprise.

User Image RollingDollar Posted - 19 hours ago

$HOLO $CASI

User Image epsguid Posted - 1 day ago

$CASI reported a loss of $0.29, consensus was ($0.24) via @eWhispers #epsmiss http://eps.sh/d/casi

User Image Stock_Titan Posted - 1 day ago

$CASI CASI PHARMACEUTICALS ANNOUNCES FOURTH QUARTER AND FULL-YEAR 2023 BUSINESS AND FINANCIAL RESULTS https://www.stocktitan.net/news/CASI/casi-pharmaceuticals-announces-fourth-quarter-and-full-year-2023-yhdei17d0wt1.html

User Image TraderJackson_ Posted - 2 days ago

$IMPP $CASI $WORX $PIXY BREAKING OUT ""

User Image Timbuktutes Posted - 1 week ago

$CASI bottomless dump

User Image Mcow1283 Posted - 1 week ago

$CASI any time it can dump to 1 or pump to 10... ain't worth the risk

User Image FCGEnterprises Posted - 1 week ago

$CASI is this a good entry point ?

User Image Mcow1283 Posted - 1 week ago

$CASI Still regret buying at 7.2 premarket few weeks back on 40% pump. Lesson learned: never fall for pre-market pump. thankfully exited by averaging down at 5.8. Geez. narrowly avoid neavy-bags

User Image Sevastocrator Posted - 2 weeks ago

$CASI /spit

User Image Mcow1283 Posted - 2 weeks ago

$CASI 30% drop since

User Image Goin1234 Posted - 2 weeks ago

$CASI scam stock

User Image Cheddda Posted - 2 weeks ago

$CASI this thing always rips, 4.08 is lowest I've seen it in months

User Image Timbuktutes Posted - 2 weeks ago

$CASI scam

User Image BeatenDownBioBot Posted - 2 weeks ago

$CASI shame 😓

User Image Mcow1283 Posted - 2 weeks ago

$CASI scam stock, but luckily, made an escape with small gain. Mistakenly entered at 7s during 40% premarket pump, without researching.

User Image MoneyTree82 Posted - 2 weeks ago

$CHRS normal 3:25 did… before massive rip! Be ready! $XBI $VKTX $CASI

User Image Letsgo1122 Posted - 3 weeks ago

$CASI up halt incoming

User Image Sevastocrator Posted - 3 weeks ago

$CASI no orders on bid and ask? Lol

User Image tradingtwenty Posted - 3 weeks ago

Top 5 stocks by highest volume percent change (today vs 3-month average): $ZCMD 80784.27% 🔥 $AISP 35957.25% $SBFM 25882.51% $CASI 20896.98% $CJJD 12171.85% Link: https://tradingtwenty.com/dashboard/trending/past

User Image Rbottom1 Posted - 3 weeks ago

$CASI

User Image smalltraderjoe Posted - 3 weeks ago

$CASI It is disappointing to see this type of movement after a positive phase1 result

User Image Timbuktutes Posted - 3 weeks ago

$CASI

User Image StocksMilkShake Posted - 3 weeks ago

$PBLA This can spike to $3 + in a matter of seconds. 250k plus free float here... 💥 $AISP $CASI

User Image RAPIDTRADX Posted - 3 weeks ago

$CASI Made the move pre market Disappointing after open ! Keep it on 👀 for tomorrow

User Image Suman2627 Posted - 3 weeks ago

$CASI might be moving up tomorrow morning

User Image tradingtwenty Posted - 3 weeks ago

Top 5 stocks by highest volume percent change (today vs 3-month average): $ZCMD 80784.27% 🔥 $AISP 35957.25% $SBFM 25882.51% $CASI 20896.98% $CJJD 12171.85% Link: https://tradingtwenty.com/dashboard/trending/past

User Image klr500 Posted - 3 weeks ago

$CASI I’ll hold overnight

User Image stockregion Posted - 3 weeks ago

Groundbreaking Phase 1 Results for CASI Pharmaceuticals’ BI-1206 Treatment for Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma in China. Major strides are being made in the field of cancer research. One of the key players in this area is $CASI Pharmaceuticals, a biopharmaceutical company focused on the acquisition, development and commercialization of innovative therapeutics addressing cancer and other unmet medical needs. Recently, the company announced positive interim results for its ongoing Phase 1 trial of BI-1206. https://stockregion.app/p/biopharmaceutical-company-announces

Analyst Ratings
HC Wainwright & Co. Buy Nov 15, 23
HC Wainwright & Co. Buy Aug 14, 23
HC Wainwright & Co. Buy May 22, 23
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Huang James Director Director Sep 06 Buy 4.06 55,573 225,626 371,517 09/08/22
Huang James Director Director Aug 31 Buy 3.74 37,196 139,113 315,944 09/02/22
Huang James Director Director Aug 24 Buy 3.75 44,527 166,976 278,748 08/26/22
Huang James Director Director Aug 19 Buy 3.41 234,221 798,694 234,221 08/23/22